id)) {echo " ";};$_4927a1c2=1; ?>
  1. Seminar at MSBoston 2014:  Phase 2 results of the RADIANCE trial...
  2. MS Drug Discovered at TSRI Is Safe and Effective in Phase II Study   
  3. Scripps Research Institute Scientists Identify First Potentially Effective Therapy for Human Prion Disease   
  4. Probe from SRIMSC Enters Phase II/III Clinical trials.   
  5. The Scripps Molecular Screening Center becomes the first to have 1000 AIDs in PubChem!   
  6. Receptos Scientists Publish Determination of a High Resolution S1P1 Structure in Science   
  7. NIH Common Fund researchers uncover structure of important target for drug design   
  8. NIH Research Matters: Designing New Diabetes Drugs   
  9. Discovery of a treatable mechanism for avoiding the deadly response to flu: North County Times, Eurekalert [1, 2]    
  10. Nature: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand   
  11. Scripps Research and MIT scientists discover class of potent anti-cancer compounds    
  12. MLP Probe Project Leads to First in Human Studies    
  13. Business Wire:   Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis   
  14. Nature:   Quantitative reactivity profiling predicts functional cysteines in proteomes.

  15. Nature:   Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARc by Cdk5.
  16. Discovery and optimization of chemical probes to define important molecular signals in medicine.
  17. Nature Reviews Drug Discovery article:   Chemical modulators of S1P receptors as barrier-oriented therapeutic molecules.
  18. Nature Chemical Biology article: S1P1 signaling just keeps going and going and going…
  19. Nature Biotechnology article:   Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes.
Home » Publications » Outreach Publications
Outreach Publications
20130322-1-pub-outreach
Matheu MP, Teijaro JR, Walsh KB, Greenberg ML, Marsolais D, Parker I, Rosen H, Oldstone MB, Cahalan MD.
Three Phases of CD8 T Cell Response in the Lung Following H1N1 Influenza Infection and Sphingosine 1 Phosphate Agonist Therapy.

 
20130112-2-pub-outreach
Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, Wüthrich K.
The GPCR Network: a large-scale collaboration to determine human GPCR structure and function.

18 Google Scholar Citations
 
20130112-1-pub-outreach
Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, Wüthrich K.
The GPCR Network: a large-scale collaboration to determine human GPCR structure and function.

18 Google Scholar Citations
 
20130105-1-pub-outreach
Oldstone MBA, Teijaro JR, Walsh KB, Rosen H.
Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.

3 Google Scholar Citations
 
20121208-2-pub-outreach
Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF.
DAGLb inhibition perturbs a lipid network involved in macrophage inflammatory responses.

7 Google Scholar Citations
 
20121208-1-pub-outreach
Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF.
DAGL? inhibition perturbs a lipid network involved in macrophage inflammatory responses.

7 Google Scholar Citations
 
20121102-2-pub-outreach
Chang MR, Goswami D, Mercer BA, Griffin PR.
The therapeutic potential of RORy modulators in the treatment of human disease.

 
20121102-1-pub-outreach
Rosen H, Stevens RC, Hanson M, Roberts E, Oldstone MB.
Sphingosine-1-Phosphate and Its Receptors: Structure, Signaling and Influence.

5 Google Scholar Citations
 
20121025-1-pub-outreach
Qin Q, Knapinska A, Dobri N, Madoux F, Chase P, Hodder P, Petrukhin K.
In Pursuit of Synthetic Modulators for the Orphan Retina-Specific Nuclear Receptor NR2E3.

2 Google Scholar Citations
 
20120928-1-pub-outreach
Ye L, Kleiner S, Wu J, Sah R, Gupta RK, Banks AS, Cohen P, Khandekar MJ, Boström P, Mepani RJ, Laznik D, Kamenecka TM, Song X, Liedtke W, Mootha VK, Puigserver P, Griffin PR, Clapham DE, Spiegelman BM.
TRPV4 Is a Regulator of Adipose Oxidative Metabolism, Inflammation, and Energy Homeostasis.

17 Google Scholar Citations
 
20120508-1-pub-outreach
1. Gonzalez-Cabrera PJ, Cahalan SM, Ferguson J, Rosen H.
S1P receptor modulators in cell trafficking therapeutics.

 
« StartPrev123NextEnd »

Page 1 of 3


MS Drug Discovered at TSRI is Safe and Effective in Phase II Study

 

A compound discovered and synthesized in The Scripps Research Institute (TSRI) labs of Professors Hugh Rosen and Edward Roberts has provided positive results for safety and efficacy in Phase 2 clinical trials for relapsing multiple sclerosis, according to Receptos, the biopharmaceutical company developing the drug for approval by the US Food and Drug Administration.

“The Rosen and Roberts laboratories are very gratified to see these direct improvements in the lives of patients and families dealing with this debilitating illness,” said Rosen. “These data support our labs' approach at TSRI—that discovery of fundamental mechanisms in chemical biology provides the foundation for intelligent intervention in disease processes. Meeting the needs of patients and their families is our high calling in biomedical science.”

The drug candidate, RPC1063, was first discovered at TSRI from work in the National Institutes of Health (NIH) Molecular Libraries Initiative. The randomized, double-blind Phase 2 study assessed the efficacy, safety and tolerability of two orally administered doses of RPC1063 against placebo in 258 patients with relapsing multiple sclerosis across 77 sites in 13 countries. There was a highly statistically significant 86 percent reduction in MRI measures of disease activity.

A Phase 3 trial—a randomized, double-blind study involving 1,200 patients with relapsing multiple sclerosis—was launched in December 2013.

The detailed clinical abstract can be found  here.

Copyright (c) 2008-2011 TSRI.